- Home
- CHNR vs XRTX Comparison
CHNR vs XRTX Comparison
Compare CHNR & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | XRTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.4M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | XRTX |
|---|---|---|
| Price | $3.94 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.1K | ★ 50.0K |
| Earning Date | 12-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $0.52 |
| 52 Week High | $8.20 | $1.79 |
Technical Indicators
Market Signals| Indicator | CHNR | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 46.07 |
| Support Level | $3.75 | $0.61 |
| Resistance Level | $4.31 | $0.67 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 43.35 | 22.06 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.